UNSPSC 51332817: Promazine

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O9M39HTM5W, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, monohydrochloride but generally known as promazine, which bears US NIH Compound Identifier 4926. European Medicines Agency schedules Promazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10085MIG.

UNSPSC 51332817 Promazine is a Commodity code that encompasses pharmaceutical procurement by state and local health agencies, though recent activity under this code shows limited direct demand for promazine itself. State and local governments are instead buying naloxone, generic multi-source pharmaceuticals, over-the-counter products, and pharmacy benefit management services through this classification. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These jurisdictions procure pharmaceuticals to support community health initiatives, employee benefit programs, and clinical operations across multiple facilities.

Geographic activity centers on Florida, Texas, Minnesota, and Oregon, with MMCAP's multistate cooperative structure extending reach across participating jurisdictions. Recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with effective contract date of July 1, 2026. Vendors responding to MMCAP contracts must maintain relationships with AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson and comply with cGMP and Drug Supply Chain Security Act requirements, with pricing evaluated on competitiveness (75 percent weight), fixed pricing (10 percent), and administrative compliance (15 percent combined).